AxisBiotix-PsT Psoriasis Food Supplement Launch

RNS Number : 4444N

SkinBioTherapeutics PLC

30 September 2021

 

30 September 2021

SkinBioTherapeutics plc

("SkinBioTherapeutics" or "the Company")

AxisBiotix-Ps™ Psoriasis Food Supplement Launch and Progress Update

· AxisBiotix-Ps™ to launch on World Psoriasis Day - 29 October 2021;

· Finished product ready in Netherlands distribution centre

· Pre-registrations for AxisBiotix-Ps continue to increase

SkinBioTherapeutics plc (AIM: SBTX), a life science company focused on skin health, has today provided a significant update on its commercialisation plans for AxisBiotix-Ps™, its probiotic food supplement   to help alleviate the symptoms associated with psoriasis, and reveals the launch date as 29 October 2021, which notably is World Psoriasis Day.

Following highly positive results from its consumer study in May 2021 , SkinBioTherapeutics has driven ahead the finalisation of the regulatory pathway and commercial strategy for AxisBiotix-Ps ™ . Key activities have included the preparation of and warehousing the finished product and commencing marketing prior to the upcoming launch, as well as establishing a supply chain.

Through its subsidiary AxisBiotix Limited ("AxisBiotix"), SkinBioTherapeutics has begun receiving and storing finished product at its distribution centre in the Netherlands. The warehouse is 10,000sq metres and is located in Boxtel near Eindhoven which has been carefully chosen for its proximity to the Company's formulation partner, Winclove and its distribution links to the US, UK and Europe. Readying of finished product is ahead of schedule for launch.

Commercialisation will commence with a 'soft launch' of AxisBiotix-Ps™ on World Psoriasis Day,
29 October 2021. As previously announced, commercialisation will start in the UK and the US markets. Sales of the product will be restricted initially to a limited number of customers from the pre-registration list to ensure a robust and reliable supply chain. Thereafter access to the eCommerce website will be opened up on a broader basis to the remainder of the waiting list and the wider psoriatic population. 

As disclosed in the business update on 19 August 2021, excluding shipping and any duty costs, AxisBiotix-Ps ™ will be marketed on a subscription basis and priced per sachet (including VAT) in the US at $2.00 (USD), in the UK £1.50 (GBP), and in Europe €1.80 (EUR) and sold in boxes containing 28 sachets.

To create a ready-made market for the product at launch, the Company has been busily ramping up the profile of the product with a multi-media marketing strategy to encourage pre-registration of interest from potential customers. This campaign has included multiple video testimonials from participants of the consumer study in May 2021, some of which can be seen HERE . Pre-registration remains open at this stage and can be accessed via the AxisBiotix website at axisbiotix.com/form .

Stuart Ashman, CEO of SkinBioTherapeutics, said:

"This is a very exciting moment for SkinBioTherapeutics as we launch our first commercial product on the most important of days for the global Psoriasis community. The overall positive response from participants who identified as having psoriasis to AxisBiotix-Ps™ was tremendous, and we are very grateful for their continued interest and subsequent support, including their moving written and video testimonials.

"The soft launch aspect of the commercial strategy is a key element. Given the incurable and severe nature of psoriasis and the significant impact on people's lives, we have always said that we would initially release AxisBiotix-Ps ™ on a controlled basis to ensure our distribution systems are robust. We want to ensure a continuous supply to our customers at all times."

In May 2021 SkinBioTherapeutics reported on the outcomes of the study for participants that self-identified as suffering from psoriasis. The results were very positive and provided definitive support for the commercial development of AxisBiotix-Ps™ as a probiotic food supplement to help alleviate the symptoms of psoriasis. Of participants that completed the study, 76% reported a reduction in itchiness and 73% reported that their skin felt less irritable. For the full report, please see HERE .

-Ends-

The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 and has been arranged for release by Doug Quinn, CFO of the Company. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

For more information please contact:

SkinBioTherapeutics plc Stuart J . Ashman, CEO Doug Quinn, CFO	Tel: [phone]
Cenkos Securities Plc (Nominated Adviser & Broker) Giles Balleny, Max Gould (Corporate Finance) Michael Johnson, Dale Bellis (Sales)	Tel: [phone]
Instinctif Partners (financial press) Melanie Toyne-Sewell / Nathan Billis	Tel: [phone] [e-mail]

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by Professor Catherine O'Neill and Professor Andrew McBain.

The Company is targeting a number of skin healthcare sectors, the most advanced of which are cosmetic skincare and food supplements to modulate the immune system by harnessing the gut-skin axis. In each area SkinBioTherapeutics plans to exemplify its technology through human studies.

The Company listed on AIM in April 2017 and is based in Manchester, UK.  For more information, visit: www.skinbiotix.com .

 

END

 

 

UPDBLGDCGXDDGBC